Latest Depression News

Nufarm reported a mixed 1H25 with a strong rebound in crop protection profits contrasting a sharp decline in seed technologies earnings, prompting a strategic review of the latter business.

Legacy Minerals has lodged an exploration licence application over the Nico Young nickel-cobalt deposit in NSW, securing a nationally significant resource with no acquisition cost. This strategic move positions the company to capitalize on future nickel and cobalt market recoveries.

An application to the Takeovers Panel challenges Pact Group Holdings’ planned ASX delisting, citing concerns over shareholder disadvantage and selective disclosure.

MC Mining reports steady progress on its Makhado hard coking coal project with key construction milestones met, while Uitkomst Colliery faces production setbacks and rising costs amid depressed coal prices.

TrivarX has launched a pivotal mental health clinical trial in partnership with the US Department of Veterans Affairs, leveraging its innovative ECG-based technology to screen for major depressive episodes. The company also secured $2.25 million in funding, positioning it for regulatory milestones ahead.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Fin Resources Limited reported subdued exploration activity in Q1 2025 amid weak lithium prices but secured $445,000 via convertible notes and outlined plans for McKenzie Springs exploration.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Tryptamine Therapeutics has secured a landmark agreement with Swinburne University to initiate the first clinical trial of its IV-infused psilocin formulation TRP-8803 for Binge Eating Disorder, aiming to build on promising Phase 2a data.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Somerset Minerals Ltd has raised $2.39 million to fund its maiden drilling and surface sampling campaign at the Coppermine copper-silver project in Nunavut, targeting high-grade mineralisation supported by strong geophysical and historical data.

ARB Corporation Limited posted a 5.9% rise in sales revenue to $361.7 million for 1H FY2025, driven by strong export growth, while profit before tax edged down 0.7% amid rising costs and subdued domestic vehicle sales.